- ERIC INTERNATIONAL MEETING 2022
- ERIC INTERNATIONAL MEETING 2020
- ERIC INTERNATIONAL MEETING 2018
Please click in the links to see the videos
Videos of the meeting:
- Highlights from the ERIC International Meeting
- Alberto Orfao_MBL – from the lab to the clinic
- Andy Rawstron_The nosology of CLL
- Antonio Cuneo_Practical considerations
- Christina Karamanidou_Patient preferences
- Iñaki Martin-Subero_A multi-omics perspective to the origin, nature and evolution of CLL
- Jennifer Brown_From bench to bedside Targeting signaling pathways
- John Seymour_From bench to bedside Targeting apoptosis
- Kanti Rai_My vision of the future of CLL
- Lukas Smolej_The host focus on frailty assessment
- Marco Ruella_Cellular therapies in CLL – present and future
- Michael Hallek, Thomas Kipps_Round table optimizing treatment outcomes Chairs
- Nicholas Chiorazzi_Immunological reflections on the origin, nature and evolution of CLL
- Othman Al-Sawaf_The tumor biomarker-guided treatment
- Peter Hillmen_Combined inhibition of signaling and anti-apoptotic pathways
- Richard Rosenquist_Early diagnosis – how genomics can assist us
- Tanja Hartmann_The microenvironment in CLL – Lessons from mouse models
- Thomas Chatzikonstantinou_Outcomes of patients with CLL developing COVID-19
- Thorsten Zenz_The molecular basis of resistance to treatment
- Yair Herishanu_Outcomes of vaccination against SARS-CoV-2
Please, click on the session to see the videos:
Chairs: Nicholas Chiorazzi, Kostas Stamatopoulos
Introduction by Federico Caligaris-Cappio
- Exploring the roads to CLL, by Freda Stevenson
- MBL: Always a one-way ticket to CLL?, by Lydia Scarfo
- CLL: One entity or more? Diagnostic considerations, by Andy Rawstron
Session II. Disease trajectories: Outcomes, possible explanations and clinical implications
Chairs: Michael Doubek, Robin Foa
- Spontaneous regression, by Tatjana Stankovic
- Clonal evolution: How is it reflected at the genome?, by Catherine J. Wu
- Richter transformation, by Davide Rossi
- CHIP and second primary myeloid malignancies, by Panagiotis Baliakas
Session III. Resistance to apoptosis
Chairs: Eric Eldering, Alan Ramsay
- The anti-apoptotic phenotype: Cell-intrinsic drivers, by Stephan Stilgenbauer
- The anti-apoptotic phenotype: Cell-extrinsic drivers, by Dimitar Efremov
- Promoting apoptosis in CLL: Clinical overview, by John Seymour
Session IV. Proliferation: What lies beneath and how to target it?
Chairs: Silvia Deaglio, Thomas Kipps
- CLL and microenvironmental addictions, by Adrian Wiestner
- Relevant bystander cells, by Martina Seiffert
- Targeting CLL cell proliferation: Clinical overview, by Jan Burger
Session V. Networking and collaboration: Why and how
Chairs: Eva Kimby, Emili Montserrat
- US initiatives, by Anthony Mato
- The ERIC CLL Database, by Anastasia Chatzidimitriou
- CLL within HARMONY, by Francesc Bosch
- EHA links to EU initiatives and infrastructures, by Ulrich Jaeger
Round table discussion: Frontline treatment: State-of-the-art
Chairs: Michael Hallek, John Seymour
Discussants: Florence Cymbalista, Matthew Davids, Kirsten Fischer, George Follows, Alessandra Tedeschi, William Wierda, Jennifer Woyach
Round table discussion: Management of relapsed/refractory disease: State-of-the-art
Chairs: Jennifer Brown, Peter Hillmen
Discussants: Antonio Cuneo, Barbara Eichhorst, Arnon Kater, Stephen Schuster, Michel van Gelder
You can see all the presentations live clicking here
You can download the presentations here:
25 October, 2018
Session 1: Setting the tone
Session 2: CLL Pathogenesis: Interacting subsystems
- CLL Diagnosis: everything settled – A. Rawstron
- Microenvironmental interactions and signaling pathways in CLL – S. Deaglio
- CLL cell dynamics – N. Chiorazzi
- Genomic discoveries in CLL – R. Rosenquist
- Aberrant cell processes in CLL-beyond genomic aberrations – I. Martín Subero
26 October, 2018
Session 3 – CLL treatment: state-of-the-art
- Pathway inhibitors for CLL therapy – J. Barrientos
- Combining treatment modalities: useful or superfluous? – W. Wierda
- Sequential therapy and mechanisms of resistance – S. Stilgenbauer
Session 4 – Looking to the future in CLL treatment
- What does the future hold – projections from real world evidence – R. Foà
- Aiming at MRD eradication why and how – P. Hillmen
Session 5 – The future of cellular therapies
27 October, 2018
Session 8 – ERIC mission: improving CLL patient care Auditorium
Research within ERIC: in the spirit of collaboration – R. Rosenquist
Setting standards: ERIC harmonization activities – S. Pospisilova